Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
46 Results for "
PLD
" in MedChemExpress (MCE) Product Catalog:
Products (46)
46 Results for "PLD" in MCE Product Catalog:
5
5 Cited Publications
Synonyms: 5-Fluoro-2-indolyl deschlorohalopemide
Target:
Research Areas:
Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
FIPI is a phospholipase D (PLD) inhibitor with an IC50 for PLD1 and PLD2 of about 25 nM. FIPI regulates cytoskeletal recombination, cell diffusion and chemotaxis. FIPI can be used in cancer research. In addition, FIPI can enhance the secretion and aggregation of platelet dense particles, inhibit thrombosis, reduce ischemic stroke infarct volume and improve nerve function .
3
3 Cited Publications
Target:
Research Areas:
LEI-401 is a first-in-class, selective, and CNS-active NAPE-PLD (N-acylphosphatidylethanolamine phospholipase D) inhibitor, with an IC50 of 27 nM. LEI-401 modulates emotional behavior in mice .
1
1 Cited Publications
Target:
Research Areas:
Halopemide is a potent phospholipase D (PLD) inhibitor, with IC50s of 220 and 310 nM for human PLD1 and PLD2, respectively. Halopemid is a dopamine receptors antagonist, and acts a psychotropic agent .
1
1 Cited Publications
Synonyms: CID-53361951; ML-270
Target:
Research Areas:
Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
VU0359595 (CID-53361951; ML-270) is a potent and selective pharmacological phospholipase D1 (PLD1) inhibitor with an IC50 of 3.7 nM. VU0359595 is >1700-fold selective for PLD1 over PLD2 (IC50 of 6.4 μM). VU0359595 can be used for the research of cancer, diabetes, neurodegenerative and inflammatory diseases .
1
1 Cited Publications
Target:
Research Areas:
APE-PLD (VU533) activator is a potent NAPE-PLD activator with an EC50 value of 0.30 µM. NAPE-PLD activator (VU533) can enhance NAPE-PLD activity and increase efferocytosis by macrophages. NAPE-PLD activator (VU533) can be used for cardiometabolic diseases research .
Target:
Research Areas:
Neurological Disease Inflammation/Immunology Endocrinology Cancer
Phospholipase D, Streptomyces chromofuscus (PLD) is an enzyme of the phospholipase superfamily, which widely exists in bacteria, yeast, plants, animals and viruses, and is often used in biochemical research. Phospholipase D can catalyze the hydrolysis of phosphodiester bonds in glycerophospholipids to produce phosphatidic acid and soluble choline. Phospholipase D is involved in a variety of disease-related processes, including diabetes, atherogenesis, obesity, tumorigenesis, immune response, and neuroendocrine function .
Synonyms: CAY10593
Target:
Research Areas:
VU0155069 (CAY10593), is a selective phospholipase D1 (PLD1) inhibitor with an IC50 value of 46 nM in vitro. VU0155069 (CAY10593) strongly inhibits the invasive migration of several cancer cell lines in transwell assays .
Target:
Research Areas:
Glycerophospholipids and cephalins are a class of phospholipid compounds and important components of neural membranes. Glycerophospholipids and cephalins are hydrolysis substrates of phospholipase (such as PLA2, PLC, and PLD). After complete hydrolysis, they produce 1 mol of glycerol, phosphate, ethanolamine, and 2 mol of fatty acids, respectively. Glycerophospholipids and cephalins can maintain membrane structure, fluidity, and ion permeability, and serve as precursors of second messengers such as arachidonic acid and diacylglycerol. Glycerophospholipids and cephalins can regulate signal transduction, cell apoptosis, and membrane transport, and are used in the study of neurodegenerative diseases (such as Alzheimer's disease) .
Target:
Research Areas:
VU534 is a NAPE-PLD activator, with an EC50 of 0.30 μM. VU534 is dual inhibitors of FAAH and sEH (IC50 of 1.2 μM). VU534 increases efferocytosis in a NAPE-PLD dependent manner. VU534 has the potential for cardiometabolic diseases study [1] .
Target:
Research Areas:
Phospholipase D, peanut is a phospholipase D (EC 3.1.4.4) of the PLD superfamily found in peanuts, acting as a phosphodiesterase and signaling enzyme with activity toward phosphatidylcholine. Phospholipase D hydrolyzes phosphatidylcholine to phosphatidic acid and choline, and catalyzes transphosphatidylation reactions. Phospholipase D can be used for the research of myocardial disease, ischemic heart disease, congestive heart failure, diabetic cardiomyopathy, cardiac hypertrophy, vascular abnormalities, breast cancer, gastric cancer, renal cancer, colorectal cancer .
Cat. No.: HY-P1341
CAS No.: 343268-91-7
Synonyms: Orexin A (17-33) (human, mouse, rat, bovine)
Research Areas:
Target:
Research Areas:
A3373, a novel chemical inhibitor of Phospholipase D1 (PLD1) and PLD2, with IC50 of 325 nM and 15.15?μM, respectively, inhibits LPS-induced immune response and plays important roles in autoimmune arthritis, bone demineralization and osteoclastogenesis .
Cat. No.: HY-RS19152
Target:
Research Areas:
Pld2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Pld2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Target:
Research Areas:
ARN19874 is a selective, reversible uncompetitive N-acylphosphatidylethanolamine phospholipase D (NAPE-PLD) activity inhibitor with an IC50 of ~34 μM .
Target:
Research Areas:
Phospholipase D, cabbage is a phospholipase D of the PLD superfamily found in cabbage, acting as a phosphodiesterase and signaling enzyme with activity toward phosphatidylcholine. Phospholipase D hydrolyzes phosphatidylcholine to phosphatidic acid and choline, and catalyzes transphosphatidylation reactions. Phospholipase D can be used for the research of myocardial disease, ischemic heart disease, congestive heart failure, diabetic cardiomyopathy, cardiac hypertrophy, vascular abnormalities, breast cancer, gastric cancer, renal cancer, colorectal cancer .
Cat. No.: HY-169262
CAS No.: 1001957-60-3
Target:
Research Areas:
PLD-IN-1 (Compound 3r) is an orally active inhibitor for phospholipase D with an IC50 of 1.97 μM. PLD-IN-1 reduces the expression of CD24, CD47 and PD-L1, enhances the calreticulin expression, and thus modulates the immune evasion mechanism in lung cancer cells by promoting the phagocytosis of cancer cells by macrophages. PLD-IN-1 inhibits the cell viability of lung cancer cell A549, HCC44, H460 and HCC15 with IC50 of 18.44, 22.31, 24.85 and 21.45 μM, respectively. PLD-IN-1 can induce apoptosis and inhibits migration in cell A549. PLD-IN-1 enhances the level of pro-inflammatory M1 macrophages and decreases the level of anti-inflammatory M2 macrophages, exhibits antitumor efficacy in mouse model .
Cat. No.: HY-RS10670
Target:
Research Areas:
PLD1 Human Pre-designed siRNA Set A contains three designed siRNAs for PLD1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS10671
Target:
Research Areas:
PLD2 Human Pre-designed siRNA Set A contains three designed siRNAs for PLD2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS10672
Target:
Research Areas:
PLD3 Human Pre-designed siRNA Set A contains three designed siRNAs for PLD3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS10673
Target:
Research Areas:
PLD4 Human Pre-designed siRNA Set A contains three designed siRNAs for PLD4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
